Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

NCT04952597 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Limited Stage Small Cell Lung Cancer

Interventions

DRUG: Ociperlimab
DRUG: Tislelizumab
DRUG: Concurrent Chemoradiotherapy

Sponsor

BeiGene